I. Company Profile:

Founded in April 2022, Beijing Huake Xianfeng Medical Device Co., Ltd. is a high-tech enterprise specializing in the field of tumor radiation therapy. With the core philosophy of "Independent Innovation, All-out Efforts, and Striving for Human Life and Health," the company is committed to optimizing clinical application scenarios of radiation therapy through technological innovation, providing safer, more precise, intelligent, and comfortable solutions for medical institutions and patients.

Based in the strategic area of Beijing-Tianjin-Hebei coordinated development, the company has established modern R&D centers in Beijing's Mentougou District and intelligent manufacturing production bases in Hebei's Langfang Airport Economic Zone, forming a "dual-core driven" industrial layout and deeply integrating into regional economic development. Relying on Beijing's scientific and technological innovation resources and the location and transportation advantages of the airport economic zone, the company has built a full-life-cycle service system covering product R&D, manufacturing, after-sales maintenance, technical training, etc., to provide efficient and reliable solutions for customers.

With technological innovation as its core driving force, the company has obtained multiple patents and industry certifications and strictly adheres to international quality standard systems.

In the future, the company will continue to deepen its technological layout, expand industrial chain collaboration, and strive to become an industry benchmark enterprise, creating long-term value for global customers!

II. Corporate Background:

In July 2022, the company undertook the industrial application of the "13th Five-Year Plan" National Key R&D Program project—"X-band High-Stability Miniaturized Radiation Source Module," developing a new generation of X-band medical linear accelerators with complete independent intellectual property rights. In October 2024, the first product, "HK-X601," passed type inspection.

In March 2023, it was approved as a Zhongguancun High-Tech Enterprise.

In 2024, the company led the "14th Five-Year Plan" National Key R&D Program project—"Technical R&D and Prototype Development of Stereotactic Radiometric Treatment Systems for Arrhythmias," collaborating with institutions such as Fuwai Hospital, Tsinghua University, Fudan University, and the PLA General Hospital to develop the world's first dedicated accelerator for cardiac radiation therapy.

In 2024, the large-field and mobile imaging systems developed by the company were delivered to customers.

In 2024, the company undertook the OEM production of components and complete machines for the "ZAP-X Mars boat Radiosurgical Robot."

III. Business Scope:

The business scope of Beijing Huake Xianfeng Medical Device Co., Ltd. mainly includes medical device production and operation, technical R&D and related services, import-export business, etc., as follows:

Medical Device Production and Operation: Engaged in the production and operation of Class II and Class III medical devices.

Technical R&D and Services: Conducting medical research and experimental development, engineering and technical research and experimental development; providing technical services, development, consulting, exchange, transfer, and promotion; software development and sales, as well as professional design services; involving industrial control computer and system manufacturing, cloud computing equipment technical services.

Other Business: Including import-export of goods and technologies, as well as leasing services (excluding licensed leasing services).

Additionally, the company focuses on providing radiation therapy solutions for systemic tumor patients. Its core project is the "4π Multi-Modal Image-Guided Robot Stereotactic Radiation Therapy System," and it carries out R&D and patent layout of related medical devices around radiation therapy technologies.

IV. Case Studies:

Founded in April 2022 and located in Mentougou District, Beijing, the company specializes in R&D of high-end radiation therapy equipment. China's first 4π intelligent robot radiation therapy system integrates a circular gantry and robotic arm to achieve 4π global radiation therapy, which has passed type inspection and is  (about to enter) clinical trials. Meanwhile, the company-led R&D project for the stereotactic radiometric treatment system for arrhythmias was selected into the national "14th Five-Year Plan" Key R&D Program, collaborating with multiple institutions to develop the world's first dedicated radiation therapy system for arrhythmias.

The company's business covers the production and operation of Class II and III medical devices, technical R&D, import-export, and related services. As of April 2025, it holds 21 patents, such as multi-modal imaging treatment devices and cone-beam imaging systems. Huake Xianfeng is an incubated enterprise of Baiyang Pharmaceutical, supported by the "Beijing Mentougou Baiyang Medical Industry Investment Fund," and plans to collaborate with ZAP Surgical in the future to achieve full-scenario coverage of radiation therapy equipment.

V. Honors & Accolades:

The main honor of Beijing Huake Xianfeng Medical Device Co., Ltd. is leading a project selected into the National Key R&D Program. The company-led project "Technical R&D and Prototype Development of Stereotactic Radiometric Treatment Systems for Arrhythmias" was successfully listed in the key special project approval list of the "14th Five-Year Plan" National Key R&D Program "Diagnostic and Treatment Equipment and Biomedical Materials" announced by the Ministry of Science and Technology. This not only demonstrates its major breakthrough in the field of cardiac radiation therapy but also reflects the company's strength in R&D of high-end medical devices.